FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANG	ES IN BENEF	ICIAL OWN	IFRSHI

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average burde	en
hours per response:	0.5
	OMB Number: Estimated average burde

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Ramasastry Saira						2. Issuer Name and Ticker or Trading Symbol SANGAMO BIOSCIENCES INC [SGMO]									all applic	onship of Reporting all applicable) Director		10% O	vner
(Last) (First) (Middle) C/O SANGAMO BIOSCIENCES INC., POINT RICHMOND TECH CNTR, 501 CANAL BLVD					06/	3. Date of Earliest Transaction (Month/Day/Year) 06/23/2014 4. If Amendment, Date of Original Filed (Month/Day/Year)									Officer (give title below)		Other (s below) p Filing (Check Ap		
(Street) RICHMOND CA 94804			- -	Form filed by One Reporting Person Form filed by More than One Reporting Person															
(City)	(Si	tate)	(Zip)																
		Tab	le I - 1	Non-Deriv	vative	Sec	uriti	ies A	cquire	ed, D	isposed c	of, or B	enefic	ially	Owned	I			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y				Execution Date,		Date,				s Acquired (A) or f (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
							Code	v	Amount	(A) or (D)	Price			saction(s) r. 3 and 4)			(Instr. 4)		
Common Stock 06/23/201					014	14			M		5,550	A	\$5.	03 5		5,550		D	
Common	Stock			06/23/2	014				S ⁽¹⁾		5,550	D	\$15.53	346 ⁽²⁾		0 D			
		1	able								posed of, , converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owne Form Direc or Ind (I) (In	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amou or Numb of Share	er					
Employee Stock Option (Right to Buy)	\$5.03	06/23/2014			M			5,550	(3	3)	06/20/2022	Common Stock	ⁿ 5,55	50	\$0.00	34,450		D	

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 14, 2014, as amended.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$15.17 to \$15.88, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- 3. Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon the cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to each option vest in monthly installments upon completion of each month of Board service over a three year period.

Remarks:

/s/ Florence Tam, attorney-infact

06/25/2014

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.